Home » FDA Slow to Ask J&J for Drug Data, Lawyer Says
FDA Slow to Ask J&J for Drug Data, Lawyer Says
Philadelphia lawyer Steven Sheller wrote a letter to the FDA, claiming that the agency is not taking concerns over Johnson & Johnson’s antipsychotic drugs risperdal and invega seriously enough.
Philly.com
Philly.com
Upcoming Events
-
07May
-
14May
-
30May